Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Evaluating Active Surveillance in Prostate Cancer
Clinical Breakthroughs

Evaluating Active Surveillance in Prostate Cancer

By Anna WilliamsMay 25, 2017
Share
Facebook Twitter Email
spore-catalona_500crop
William Catalona, MD, professor of Urology, was a co-author of the paper published in the Journal of Clinical Oncology.

Younger men with prostate cancer had a decreased risk of cancer progression while under active surveillance, compared to men older than 60, according to a study published in the Journal of Clinical Oncology.

William Catalona, MD, professor of Urology, was a co-author of the paper, which preliminarily suggests that active surveillance — where low-risk prostate cancer is closely monitored and treated only if the disease progresses — may be a beneficial strategy, at least in the short term, to reduce overtreatment in some younger patients.

Prostate cancer, which affects one in seven men during their lifetime, often grows very slowly. As such, some men with localized, early-stage prostate cancer may not benefit from immediate treatment, such as surgery or radiation therapy, which can also carry side effects that impact quality of life.

In these cases, active surveillance may be an option: delaying treatment, while still monitoring for signs of cancer progression with blood tests and biopsies.

Although the strategy is increasingly being chosen as the course of action for low-risk cancers, and in men with shorter life expectancies, studies evaluating the suitability of active surveillance in younger men have previously been limited.

In the current study, the investigators evaluated the association of a patient’s age with their risk of disease progression while under active surveillance. More than 1,400 patients at the University of California, San Francisco, were followed for a median of 49 months. Progression rates were evaluated using Gleason scores, a system of grading prostate cancer cells.

The investigators found that patients who were 60 or younger at the time of diagnosis had a 7 percent decreased risk of an upgraded Gleason score — indicating cancer progression — during active surveillance, compared to men older than 60 years old. The two age groups, however, had similar rates of definitive treatment during the study period.

The authors note that active surveillance may be a strategy to avoid, or at least delay, treatment in some younger men with lower-risk prostate cancer, who also have higher baseline levels of urinary and sexual quality of life, and would potentially have to endure treatment-related side effects for a longer period of time.

“This is a preliminary and somewhat paradoxical finding,” Catalona said. “Generally, active surveillance has been recommended only for men over the age of 65, because their shorter life expectancy would be expected to provide less time for prostate cancer progression to cause suffering or death. However, since prostate cancer behaves more aggressively in older men, they experience early cancer progression more frequently. A caveat concerning the early results of this study — with only a median of four years of follow-up — is that longer-term follow-up may reveal higher cancer progression rates in younger men.”

Catalona is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He is principal investigator of the Lurie Cancer Center’s Specialized Program of Research Excellence (SPORE) in prostate cancer.

The research was supported by the U.S. Department of Defense Transformative Impact Aware Prostate Cancer Research Program Grant No. W81XWH-13-2-0074; National Cancer Institute Grants No. P50 CA1809952, U01CA089600-10A1 and P30CA60553; and the Urological Research Foundation.

Cancer Research Urology
Share. Facebook Twitter Email

Related Posts

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Comments are closed.

Latest News

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.